Overview:
Wounds inflicted due to gunshots are very painful and life-threatening if not given immediate medical attention. Hemorrhage or profuse blood loss is the chief cause of mortality seen in military warfare. Rapid and effective management of hemorrhage results in a lifesaving endeavor. Currently there is a rise in the number of criminal violence and accidents occurring which leads to mass killing and traumatic injury which propels the gunshot wounds injury treatment products market growth. The management of gunshot wounds is a critical procedure which involves observation such as determine if there is occurrence of flash bleed, check for vital signs and investigate if there is burn to tissues, pallor and swelling.
The Chicago Tribune in its latest survey has reported that each week in the United States approximately 1,600 people are treated in trauma centers for gunshot wounds. Brady report for 2016 states that in the United States, each year, 34,000 people die due to gunshot injuries, while 81,000 people survive. Post World War II, United States has been engaged in several wars in the Middle East and Afghanistan and has received tremendous casualties with soldiers succumbing to gunshot wounds. In April 2014, USFDA had approved XSTAT 30 manufactured by RevMedx, Inc., is a revolutionary hemostatic device, which is used for the treatment of shrapnel and gunshot wounds. It comprises of small groups of expanding sponges containing x-ray markers and is directly injected in the wound cavity. It temporarily creates a barrier for blood loss providing hemostatic pressure and is effective for 4 hours before patient receives medical surgery.
The global gunshot injuries treatment products market is segmented on the following bases:
Key players identified for global gunshot injuries treatment products market includes:
The key players set to make a mark in global gunshot wounds market are RevMedx, Inc. and Baxter Healthcare Corporation.
This report offers: